I find the discussion of the sharing arrangement with LFB to be a bit vague in the proxy and hope you can help. It talks about developing jointly to share profits then talks about exclusive rights in Europe for LFB ======================================================== Reading the proxy please clarify what it means that LFB gets exclusive European commercial rights. What benifit from Europe sales of rhFVIIa does GTCB expect?
What is GTCB expected to spend to develop rhFVIIa in Europe as part of this agreement, perhaps the production system contribution will not be very expensive?
What help can we expect from LFB when GTCB goes for US FDA approval...sharing of clinical/regulatory info from Europe?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.